Alzheimer’s disease is characterized by the deposition of amyloid-β (Aβ) peptide in the brain. The only available methods to reliably determine the levels of Aβ deposition are Aβ-PET imaging or measurement of Aβ levels in the cerebrospinal fluid. Therefore, identifying a blood-based biomarker that can be assessed in a minimally invasive and cost-effective manner is highly desirable. Katsuhiko Yanagisawa and colleagues use immunoprecipitation and mass spectrometry to measure the levels of several Aβ-related peptide fragments in blood. The APP669–711/Aβ1–42 and Aβ1–40/Aβ1–42 ratios and a composite score reliably predict individual levels of Aβ deposition in the brain. These results highlight the potential clinical utility of plasma biomarkers in predicting brain Aβ burden at an individual level.
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease (Letter p249, doi: 10.1038/nature25456)
Recent Hot Topics
- Aug 9Xenon isotopes reveal history of volatile recycling into the mantle
- Aug 2Succinate goes in to BAT, turning up the heat on metabolic disease
- Jul 26Histidine metabolism determines sensitivity to methotrexate
- Jul 19Vein-to-artery cell fate switching examined
- Jul 12Replication fork speed causes genomic instability
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.